389 related articles for article (PubMed ID: 17638918)
61. Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
Warmuth M; Danhauser-Riedl S; Hallek M
Ann Hematol; 1999 Feb; 78(2):49-64. PubMed ID: 10089019
[TBL] [Abstract][Full Text] [Related]
62. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
[TBL] [Abstract][Full Text] [Related]
63. Critical role for Gab2 in transformation by BCR/ABL.
Sattler M; Mohi MG; Pride YB; Quinnan LR; Malouf NA; Podar K; Gesbert F; Iwasaki H; Li S; Van Etten RA; Gu H; Griffin JD; Neel BG
Cancer Cell; 2002 Jun; 1(5):479-92. PubMed ID: 12124177
[TBL] [Abstract][Full Text] [Related]
64. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors.
Dorsey JF; Cunnick JM; Lanehart R; Huang M; Kraker AJ; Bhalla KN; Jove R; Wu J
Leukemia; 2002 Sep; 16(9):1589-95. PubMed ID: 12200668
[TBL] [Abstract][Full Text] [Related]
65. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis.
Sattler M; Verma S; Byrne CH; Shrikhande G; Winkler T; Algate PA; Rohrschneider LR; Griffin JD
Mol Cell Biol; 1999 Nov; 19(11):7473-80. PubMed ID: 10523635
[TBL] [Abstract][Full Text] [Related]
66. Molecular mechanisms of tumor progression in chronic myeloproliferative disorders.
Gaidano G; Guerrasio A; Serra A; Rege-Cambrin G; Saglio G
Leukemia; 1994 Apr; 8 Suppl 1():S27-9. PubMed ID: 8152300
[TBL] [Abstract][Full Text] [Related]
67. Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.
Era T; Witte ON
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1737-42. PubMed ID: 10677527
[TBL] [Abstract][Full Text] [Related]
68. BCR/ABL- CD34(+)HLA-DR- progenitor cells in early chronic phase, but not in more advanced phases, of chronic myelogenous leukemia are polyclonal.
Delforge M; Boogaerts MA; McGlave PB; Verfaillie CM
Blood; 1999 Jan; 93(1):284-92. PubMed ID: 9864172
[TBL] [Abstract][Full Text] [Related]
69. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia.
Bedi A; Zehnbauer BA; Collector MI; Barber JP; Zicha MS; Sharkis SJ; Jones RJ
Blood; 1993 Jun; 81(11):2898-902. PubMed ID: 8499629
[TBL] [Abstract][Full Text] [Related]
70. GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway.
Shi CS; Tuscano JM; Witte ON; Kehrl JH
Blood; 1999 Feb; 93(4):1338-45. PubMed ID: 9949177
[TBL] [Abstract][Full Text] [Related]
71. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Cortez D; Kadlec L; Pendergast AM
Mol Cell Biol; 1995 Oct; 15(10):5531-41. PubMed ID: 7565705
[TBL] [Abstract][Full Text] [Related]
72. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
Peng C; Li S
Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
[TBL] [Abstract][Full Text] [Related]
73. [Construction of 293pT2-P210 cell line enables expression of bcr/abl to be regulated by Tet-off inducing-expression-system].
Huang WR; Lu ZZ; Wang LS; Wang H; Duan HF; Li QF; Gao CJ; DA WM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):224-8. PubMed ID: 17493320
[TBL] [Abstract][Full Text] [Related]
74. Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays.
Ghaffari S; Daley GQ; Lodish HF
Leukemia; 1999 Aug; 13(8):1200-6. PubMed ID: 10450747
[TBL] [Abstract][Full Text] [Related]
75. Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming.
Chalandon Y; Jiang X; Hazlewood G; Loutet S; Conneally E; Eaves A; Eaves C
Blood; 2002 May; 99(9):3197-204. PubMed ID: 11964283
[TBL] [Abstract][Full Text] [Related]
76. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.
de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT
Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209
[TBL] [Abstract][Full Text] [Related]
77. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
Appel S; Boehmler AM; Grünebach F; Müller MR; Rupf A; Weck MM; Hartmann U; Reichardt VL; Kanz L; Brümmendorf TH; Brossart P
Blood; 2004 Jan; 103(2):538-44. PubMed ID: 14504105
[TBL] [Abstract][Full Text] [Related]
78. New understanding of the pathogenesis of CML: a prototype of early neoplasia.
Clarkson BD; Strife A; Wisniewski D; Lambek C; Carpino N
Leukemia; 1997 Sep; 11(9):1404-28. PubMed ID: 9305592
[TBL] [Abstract][Full Text] [Related]
79. Expansion of senescent megakaryocyte-lineage cells maintains CML cell leukemogenesis.
Tanabe Y; Kawamoto S; Takaku T; Morishita S; Hirao A; Komatsu N; Hara E; Mukaida N; Baba T
Blood Adv; 2020 Dec; 4(24):6175-6188. PubMed ID: 33351113
[TBL] [Abstract][Full Text] [Related]
80. The 30/35 kDa chymotryptic fragment of fibronectin enhances retroviral-mediated gene transfer in purified chronic myelogenous leukemia bone marrow progenitors.
Traycoff CM; Srour EF; Dutt P; Fan Y; Cornetta K
Leukemia; 1997 Jan; 11(1):159-67. PubMed ID: 9001433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
